Normal view MARC view ISBD view

Pharmacokinetics and safety of TP10, soluble complement receptor 1, in infants undergoing cardiopulmonary bypass. [electronic resource]

By:

Li, Jennifer S

Contributor(s):

Producer: 20040123Description: 173-80 p. digitalISSN:

1097-6744

Subject(s):

Online resources:

Available from publisher's website

In: American heart journal vol. 147

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

No physical items for this record

Publication Type: Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study

There are no comments on this title.

to post a comment.

Back to results

13921 Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia.
by Nijenhuis, Tom
13922 Induction of tolerance in a rat model of laryngeal transplantation.
by Akst, Lee M
13923 Current status and perspective of liver preservation solutions.
by Feng, Xiao-Ning
13924 Strain-specific differences in the effects of cyclosporin A and FK506 on the survival and regeneration of axotomized retinal ganglion cells in adult rats.
by Cui, Q
13925 Sustained response to rituximab of autoimmune hemolytic anemia associated with antiphospholipid syndrome.
by Erdozain, J G
13926 Epstein-Barr virus DNA load and seroconversion in pediatric renal transplantation with tacrolimus immunosuppression.
by Suzuki, Toshiaki
13927 A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.
by Watson, Christopher J E
13928 Effect of certain immunosuppressants on non-specific immunity cells in murine corneal grafts: study on early phases after transplantation.
by Bysterská, P
13929 Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia.
by Pillet, A
13930 1% pimecrolimus, 0.005% calcipotriol, and 0.1% betamethasone in the treatment of intertriginous psoriasis: a double-blind, randomized controlled study.
by Kreuter, Alexander
13931 FK506 binding protein 12/12.6 depletion increases endothelial nitric oxide synthase threonine 495 phosphorylation and blood pressure.
by Long, Cheng
13932 A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
by Farney, Alan
13933 The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.
by Ring, Johannes
13934 Tacrolimus and methotrexate for the prophylaxis of graft-versus-host disease after unrelated donor cord blood transplantation for adult patients with hematologic malignancies.
by Mori, T
13935 [Acute promyelocytic leukemia after living donor partial orthotopic liver transplantation].
by Sato, Tomonobu
13936 Pimecrolimus: skin disposition after topical administration in minipigs in vivo and in human skin in vitro.
by Gschwind, Hans-Peter
13937 Absence of influence of concomitant administration of rabeprazole on the pharmacokinetics of tacrolimus in adult living-donor liver transplant patients: a case-control study.
by Hosohata, Keiko
13938 Injections of vehicle, but not cyclosporin A or tacrolimus (FK506), afford neuroprotection following injury in the developing rat brain.
by Setkowicz, Zuzanna
13939 Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients.
by Gurk-Turner, Cheryle
13940 Nebulization of nanoparticulate amorphous or crystalline tacrolimus--single-dose pharmacokinetics study in mice.
by Sinswat, Prapasri